Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

286 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic significance of C-reactive protein in unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab.
Kaneko S, Asahina Y, Murakawa M, Ueyama S, Maeyashiki C, Watanabe H, Kusano-Kitazume A, Sato A, Uchidate K, Asakawa T, Watanabe S, Iizuka Y, Shibata I, Oooka S, Karakama Y, Fujii T, Watabe T, Akahoshi K, Tanabe M, Inada K, Mochida T, Watakabe K, Shimizu T, Tsuchiya J, Miyoshi M, Kitahata-Kawai F, Nitta S, Nakagawa M, Kakinuma S, Okamoto R; Ochanomizu Liver Conference Study Group. Kaneko S, et al. Among authors: asahina y. Hepatol Res. 2024 Jun;54(6):562-574. doi: 10.1111/hepr.14001. Epub 2024 Jan 11. Hepatol Res. 2024. PMID: 38133587
Assessment of Kupffer cells by ferumoxides-enhanced MR imaging is beneficial for diagnosis of hepatocellular carcinoma: comparison of pathological diagnosis and perfusion patterns assessed by CT hepatic arteriography and CT arterioportography.
Asahina Y, Izumi N, Uchihara M, Noguchi O, Ueda K, Inoue K, Nishimura Y, Tsuchiya K, Hamano K, Itakura J, Himeno Y, Koike M, Miyake S. Asahina Y, et al. Hepatol Res. 2003 Nov;27(3):196-204. doi: 10.1016/s1386-6346(03)00261-4. Hepatol Res. 2003. PMID: 14585396
Mutations in the NS5B region of the hepatitis C virus genome correlate with clinical outcomes of interferon-alpha plus ribavirin combination therapy.
Hamano K, Sakamoto N, Enomoto N, Izumi N, Asahina Y, Kurosaki M, Ueda E, Tanabe Y, Maekawa S, Itakura J, Watanabe H, Kakinuma S, Watanabe M. Hamano K, et al. Among authors: asahina y. J Gastroenterol Hepatol. 2005 Sep;20(9):1401-9. doi: 10.1111/j.1440-1746.2005.04024.x. J Gastroenterol Hepatol. 2005. PMID: 16105128
A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis.
Kurosaki M, Matsunaga K, Hirayama I, Tanaka T, Sato M, Yasui Y, Tamaki N, Hosokawa T, Ueda K, Tsuchiya K, Nakanishi H, Ikeda H, Itakura J, Takahashi Y, Asahina Y, Higaki M, Enomoto N, Izumi N. Kurosaki M, et al. Among authors: asahina y. Hepatol Res. 2010 Apr;40(4):251-60. doi: 10.1111/j.1872-034X.2009.00607.x. Epub 2010 Jan 11. Hepatol Res. 2010. PMID: 20070391
Hepatic steatosis in chronic hepatitis C is a significant risk factor for developing hepatocellular carcinoma independent of age, sex, obesity, fibrosis stage and response to interferon therapy.
Kurosaki M, Hosokawa T, Matsunaga K, Hirayama I, Tanaka T, Sato M, Yasui Y, Tamaki N, Ueda K, Tsuchiya K, Kuzuya T, Nakanishi H, Itakura J, Takahashi Y, Asahina Y, Enomoto N, Izumi N. Kurosaki M, et al. Among authors: asahina y. Hepatol Res. 2010 Sep;40(9):870-7. doi: 10.1111/j.1872-034X.2010.00692.x. Hepatol Res. 2010. PMID: 20887591
Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors.
Kurosaki M, Tanaka Y, Nishida N, Sakamoto N, Enomoto N, Honda M, Sugiyama M, Matsuura K, Sugauchi F, Asahina Y, Nakagawa M, Watanabe M, Sakamoto M, Maekawa S, Sakai A, Kaneko S, Ito K, Masaki N, Tokunaga K, Izumi N, Mizokami M. Kurosaki M, et al. Among authors: asahina y. J Hepatol. 2011 Mar;54(3):439-48. doi: 10.1016/j.jhep.2010.07.037. Epub 2010 Sep 19. J Hepatol. 2011. PMID: 21129805
Changes in hepatitis C viral load during first 14 days can predict the undetectable time point of serum viral load by pegylated interferon and ribavirin therapy.
Itakura J, Asahina Y, Tamaki N, Hirayama I, Yasui Y, Tanaka T, Sato M, Ueda K, Kuzuya T, Tsuchiya K, Nakanishi H, Kurosaki M, Gabriel GS, Schneider GJ, Izumi N. Itakura J, et al. Among authors: asahina y. Hepatol Res. 2011 Mar;41(3):217-24. doi: 10.1111/j.1872-034X.2010.00768.x. Hepatol Res. 2011. PMID: 21338453
286 results